BR112019004269A2 - composição farmacêutica compreendendo rosuvastatina e ezetimiba e método para sua preparação - Google Patents
composição farmacêutica compreendendo rosuvastatina e ezetimiba e método para sua preparaçãoInfo
- Publication number
- BR112019004269A2 BR112019004269A2 BR112019004269A BR112019004269A BR112019004269A2 BR 112019004269 A2 BR112019004269 A2 BR 112019004269A2 BR 112019004269 A BR112019004269 A BR 112019004269A BR 112019004269 A BR112019004269 A BR 112019004269A BR 112019004269 A2 BR112019004269 A2 BR 112019004269A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- ezetimibe
- rosuvastatin
- fluorophenyl
- preparation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940074795 rosuvastatin and ezetimibe Drugs 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 230000009897 systematic effect Effects 0.000 abstract 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960000815 ezetimibe Drugs 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- -1 n-methylmethanesulfonamido Chemical group 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 abstract 1
- 229960000672 rosuvastatin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a invenção refere-se a uma composição farmacêutica compreendendo os ingredientes ativos rosuvastatina de fórmula i, com o nome sistemático (3r, 5s, 6e) -7-[4-(4-fluorofenil)-2-(n-methylmethanesulfonamido)-6-(propano-2-il) pirimidin-5-il]-3,5-di-hidroxi-6-enco ou seus sais farmaceuticamente aceitáveis, ésteres, hidratos ou solvatos, e ezetimiba de fórmula ii, com o nome sistemático (3r, 4s)-1-(4-fluorofenil)-3-[(3s)-3-(4-fluorofenil)-3-hidroxipropil]-4-(4-hidroxifenil) azetidin-2-ona ou do seu sais, ésteres, hidratos ou solvatos farmaceuticamente aceitáveis, bem como um método de preparação da presente composição farmacêutica. a proporção em peso das camadas é de 1: 2 a 2: 1. (i), (ii).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2016-539A CZ2016539A3 (cs) | 2016-09-05 | 2016-09-05 | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
| PCT/CZ2017/050037 WO2018041282A1 (en) | 2016-09-05 | 2017-08-31 | A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019004269A2 true BR112019004269A2 (pt) | 2019-06-04 |
Family
ID=59955311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019004269A BR112019004269A2 (pt) | 2016-09-05 | 2017-08-31 | composição farmacêutica compreendendo rosuvastatina e ezetimiba e método para sua preparação |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11786526B2 (pt) |
| EP (1) | EP3506888A1 (pt) |
| JP (1) | JP7094944B2 (pt) |
| KR (1) | KR102517765B1 (pt) |
| CN (1) | CN110418637A (pt) |
| BR (1) | BR112019004269A2 (pt) |
| CZ (1) | CZ2016539A3 (pt) |
| EA (1) | EA201990652A1 (pt) |
| IL (1) | IL265172B (pt) |
| MA (1) | MA46100A (pt) |
| MX (1) | MX2019002516A (pt) |
| TW (1) | TWI811195B (pt) |
| WO (1) | WO2018041282A1 (pt) |
| ZA (1) | ZA201901342B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7115825B2 (ja) * | 2017-06-28 | 2022-08-09 | 日医工株式会社 | エゼチミブ含有経口製剤及びその製造方法 |
| JP2019014700A (ja) * | 2017-07-11 | 2019-01-31 | 大原薬品工業株式会社 | エゼチミブ含有口腔内崩壊錠及びその製造方法 |
| BR112022001783A2 (pt) | 2019-07-31 | 2022-03-22 | Tecnimede Soc Tecnico Medicinal Sa | Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos. |
| EP4188338A1 (en) * | 2020-07-27 | 2023-06-07 | KRKA, d.d., Novo mesto | Bilayer tablet comprising ezetimibe and atorvastatin |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1512394B1 (en) * | 2003-09-01 | 2008-03-26 | JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Universal controlled-release composition comprising chitosan |
| WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2168573A1 (en) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
| EP2448919A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| EP2459175B1 (en) * | 2009-07-28 | 2017-11-01 | Egis Gyógyszergyár Zrt. | New granulating process and thus prepared granulate |
| TR201009397A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
| WO2013066279A1 (en) | 2011-10-13 | 2013-05-10 | Mahmut Bilgic | Solid dosage forms comprising ezetimibe |
| MX365046B (es) * | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares. |
| MX2012014970A (es) * | 2012-12-18 | 2013-08-27 | Hetlabs Mexico S A De C V | Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso. |
| HU231036B1 (hu) * | 2013-09-30 | 2019-12-30 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény |
| CN103585157B (zh) * | 2013-11-13 | 2016-02-03 | 武汉武药科技有限公司 | 一种含依折麦布和瑞舒伐他汀的双层片及其制备方法 |
| KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| KR101977785B1 (ko) | 2014-06-25 | 2019-05-14 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 |
| FR3030251B1 (fr) * | 2014-12-22 | 2018-11-02 | L'oreal | Composition comprenant un compose 4-(heterocycloalkyl)-benzene-1,3-diol et un solvant particulier |
| CN105310993A (zh) | 2015-11-17 | 2016-02-10 | 深圳信立泰药业股份有限公司 | 一种含有依折麦布的药物组合物及其制备方法 |
-
2016
- 2016-09-05 CZ CZ2016-539A patent/CZ2016539A3/cs unknown
-
2017
- 2017-08-31 IL IL265172A patent/IL265172B/en unknown
- 2017-08-31 JP JP2019512660A patent/JP7094944B2/ja active Active
- 2017-08-31 EP EP17771980.4A patent/EP3506888A1/en active Pending
- 2017-08-31 KR KR1020197009428A patent/KR102517765B1/ko active IP Right Grant
- 2017-08-31 BR BR112019004269A patent/BR112019004269A2/pt active Search and Examination
- 2017-08-31 EA EA201990652A patent/EA201990652A1/ru unknown
- 2017-08-31 US US16/330,268 patent/US11786526B2/en active Active
- 2017-08-31 WO PCT/CZ2017/050037 patent/WO2018041282A1/en active Application Filing
- 2017-08-31 MA MA046100A patent/MA46100A/fr unknown
- 2017-08-31 CN CN201780067887.8A patent/CN110418637A/zh active Pending
- 2017-08-31 TW TW106129702A patent/TWI811195B/zh active
- 2017-08-31 MX MX2019002516A patent/MX2019002516A/es unknown
-
2019
- 2019-03-04 ZA ZA2019/01342A patent/ZA201901342B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3506888A1 (en) | 2019-07-10 |
| ZA201901342B (en) | 2020-10-28 |
| CN110418637A (zh) | 2019-11-05 |
| JP2019526591A (ja) | 2019-09-19 |
| US20200009136A1 (en) | 2020-01-09 |
| US11786526B2 (en) | 2023-10-17 |
| JP7094944B2 (ja) | 2022-07-04 |
| KR20190045286A (ko) | 2019-05-02 |
| WO2018041282A1 (en) | 2018-03-08 |
| KR102517765B1 (ko) | 2023-04-03 |
| MX2019002516A (es) | 2019-06-17 |
| EA201990652A1 (ru) | 2019-08-30 |
| MA46100A (fr) | 2019-07-10 |
| TWI811195B (zh) | 2023-08-11 |
| IL265172B (en) | 2022-09-01 |
| TW201818938A (zh) | 2018-06-01 |
| CZ2016539A3 (cs) | 2018-03-14 |
| IL265172A (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019004269A2 (pt) | composição farmacêutica compreendendo rosuvastatina e ezetimiba e método para sua preparação | |
| EA202190086A1 (ru) | Соединения-антагонисты pcsk9 | |
| BR112016003229A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112019009129A2 (pt) | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina | |
| BR112015020787A2 (pt) | inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico | |
| EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
| BR112016014760A2 (pt) | composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| BR112015001528A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| MX341482B (es) | Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| EA201490630A1 (ru) | 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы | |
| PH12019502111A1 (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| MX341577B (es) | Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero. | |
| MX2015013328A (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago. | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| EA201070543A1 (ru) | Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств | |
| MX2013008531A (es) | Nuevos compuestos de benzodioxol-piperazina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |